$MOBI

Green Park & Golf Ventures II, LLC purchased $1.2M of MOBI (indirect holdings)

Green Park & Golf Ventures II, LLC purchased 81,000 indirectly-held shares of Mobia Medical, Inc. (MOBI) at $15.00 ($1.22M total) on 2026-05-11.

Original reporting
SEC EDGAR · Green Park & Golf Ventures II, LLC
Published Jun 29, 2026, 11:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 11:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MOBI
Bullish
medium confidence
Mentioned
$MOBI
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBIBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase by a 10% owner at a stated price and share count; it may modestly support sentiment but does not change fundamentals in the text.

02

Market read

Traders may treat the filing as a small positive sentiment input, but it is unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

The article provides no follow-on intent, no change in control, and no confirmation of whether the buyer’s stake is part of a broader accumulation program.

Relevance 7/10Novelty 5/10Timing: Filed 2026-06-29; transaction dated 2026-05-11.

Background

This is an SEC Form 4 insider transaction disclosure tied to Mobia Medical, Inc. (MOBI).

Company-level read

Ticker impact

$MOBIBullishMedium confidence
Context

Mobia Medical, Inc. (MOBI) disclosed a Form 4 showing Green Park & Golf Ventures II, LLC (10% owner) bought 81,000 shares at $15.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus fundamentals.

Evidence & confidence

The filing is primary-source and specific (81,000 shares, $1.215M), but it lacks new guidance, contracts, or regulatory/clinical milestones.

Market effects

No clear sector read-across; this is a single-company ownership transaction.

None indicated.

None indicated.

Counterpoint

A 10b5-1 plan is explicitly marked as “No,” but the purchase could still be routine rebalancing rather than a forward-looking signal.

Key entities

  • Mobia Medical, Inc.

    Subject of the Form 4 insider transaction disclosure (MOBI).

  • Green Park & Golf Ventures II, LLC

    Reported open-market purchase of 81,000 shares (indirect holdings) on 2026-05-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

$MOBIMed

Mobia Medical, Inc. (MOBI): Results of Operations and Financial Condition

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re

$MOBIMedAI 8/10

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.